Signal mechanisms of vascular remodeling in the development of pulmonary arterial hypertension

Journal of Cardiovascular Pharmacology

Volumn 67, Issue 2, 2016, Pages 182-190

  Wang, Yong ^a   Li, Ming Xing ^a   Jiang, De Qi ^a,b   Wang, Yan ^a   Chen, Qing Zhuang ^c   Ma, Yan Jiao ^a   Yu, Shan Shan ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b YULIN NORMAL UNIVERSITY   (China)

^c Guangzhou Integrated Traditional and Western Hospital   (China)

Author keywords

Proliferation; Pulmonary artery hypertension; Signal mechanisms; Signaling pathway inhibitors; Vascular remodeling

Indexed keywords

JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; STAT PROTEIN; TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR BETA; AUTACOID;

ARTERIAL PRESSURE; DNA DAMAGE; DRUG TARGETING; HEART RIGHT VENTRICLE; HISTOPATHOLOGY; HUMAN; LUNG VASOCONSTRICTION; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PULMONARY ARTERY SMOOTH MUSCLE CELL; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; VASCULAR REMODELING; WNT SIGNALING PATHWAY; ANIMAL; METABOLISM; PATHOLOGY; PHYSIOLOGY; PULMONARY ARTERY; VASCULAR SMOOTH MUSCLE;

ANIMALS; DNA DAMAGE; HUMANS; HYPERTENSION, PULMONARY; INFLAMMATION MEDIATORS; MUSCLE, SMOOTH, VASCULAR; PULMONARY ARTERY; SIGNAL TRANSDUCTION; VASCULAR REMODELING;

EID: 84958746579     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000328     Document Type: Review

References (98)

1. Bienertova-Vasku J, Novak J, Vasku A. MicroRNAs in pulmonary arterial hypertension: pathogenesis, diagnosis and treatment. J Am Soc Hypertens. 2015;9:221-234.
2. Tuder RM, Archer SL, Dorfmüller P, et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D4-D12.
3. Bonnet S, Neyron A, Paulin R, et al. Signal transduction in the development of pulmonary arterial hypertension. Pulm Circ. 2013;3:278-293.
4. Pabani S, Mousa SA. Current and future treatment of pulmonary hypertension. Drugs Today (Barc). 2012;48:133-147.
5. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem. 1998;67:481-507.
6. Kumar CC, Madison V. AKT crystal structure and AKT-specific inhibitors. Oncogene. 2005;24:7493-7501.
7. Han F, Lin S, Liu P, et al. Synthesis and structure-activity relationships of PI3K/mTOR dual inhibitors from a series of 2-amino-4-methylpyrido[2,3-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2014;24:4538-4541.
8. Garat CV, Crossno JT, Sullivan TM, et al. Inhibition of phosphatidyli-nositol 3-kinase/Akt signaling attenuates hypoxia-induced pulmonary artery remodeling and suppresses CREB depletion in arterial smooth muscle cells. J Cardiovasc Pharmacol. 2013;62:539-548.
9. Liu Y, Fanburg BL. Serotonin-induced growth of pulmonary artery smooth muscle requires activation of phosphatidylinositol 3-kinase/ser-ine-threonine protein kinase B/mammalian target of rapamycin/p70 ribo-somal S6 kinase 1. Am J Respir Cell Mol Biol. 2006;34:182-191.
10. Goncharova EA, Ammit AJ, Irani C, et al. PI3K is required for proliferation and migration of human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2002;283:L354-L363.
11. Oudit G. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol. 2004;37:449-471.
12. Luo C, Yi B, Bai L, et al. Suppression of Akt1 phosphorylation by adenoviral transfer of the PTEN gene inhibits hypoxia-induced proliferation of rat pulmonary arterial smooth muscle cells. Biochem Biophys Res Commun. 2010;397:486-492.
13. Antoniu SA. Targeting RhoA/ROCK pathway in pulmonary arterial hypertension. Expert Opin Ther Targets. 2012;16:355-363.
14. Oka M, Fagan KA, Jones PL, et al. Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. Br J Pharmacol. 2008;155: 444-454.
15. Liu AJ, Ling F, Wang D, et al. Fasudil inhibits platelet-derived growth factor-induced human pulmonary artery smooth muscle cell proliferation by up-regulation of p27kip(1) via the ERK signal pathway. Chin Med J (Engl). 2011;124:3098-3104.
16. Yu L, Quinn DA, Garg HG, et al. Heparin inhibits pulmonary artery smooth muscle cell proliferation through guanine nucleotide exchange factor-H1/RhoA/Rho Kinase/p27. Am J Respir Cell Mol Biol. 2011;44: 524-530.
17. Connolly MJ, Aaronson PI. Key role of the RhoA/Rho kinase system in pulmonary hypertension. Pulm Pharmacol Ther. 2011;24:1-14.
18. Igaz P, Toth S, Falus A. Biological and clinical significance of the JAKSTAT pathway; lessons from knockout mice. Inflamm Res. 2001;50: 435-441.
19. Kiu H, Nicholson SE. Biology and significance of the JAK/STAT signalling pathways. Growth Factors. 2012;30:88-106.
20. Wang G, Qian G, Zhou D, et al. JAK-STAT signaling pathway in pulmonary arterial smooth muscle cells is activated by hypoxia. Cell Biol Int. 2005;29:598-603.
21. Courboulin A, Paulin R, Giguere NJ, et al. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med. 2011;208:535-548.
22. Paulin R, Meloche J, Jacob MH, et al. Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol. 2011;301:H1798-H1809.
23. Paulin R, Meloche J, Courboulin A, et al. Targeting cell motility in pulmonary arterial hypertension. Eur Respir J. 2014;43:531-544.
24. Courboulin A, Tremblay VL, Barrier M, et al. Kruppel-like factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension. Respir Res. 2011;12:128.
25. Daskoulidou N, Zeng B, Berglund LM, et al. High glucose enhances store-operated calcium entry by upregulating ORAI/STIM via calcineurin-NFAT signalling. J Mol Med. 2015;93:511-521.
26. Hou X, Chen J, Luo Y, et al. Silencing of STIM1 attenuates hypoxia-induced PASMCs proliferation via inhibition of the SOC/Ca2+/NFAT pathway. Respir Res. 2013;14:2.
27. Ran Y, Wu H, Wei L, et al. NFATc3 pathway participates in the process that 15-LO/15-HETE protects pulmonary artery smooth muscle cells against apoptosis during hypoxia. J Recept Signal Transduct Res. 2014;34:270-282.
28. Li M, Liu Y, Sun X, et al. Sildenafil inhibits calcineurin/NFATc2-mediated cyclin A expression in pulmonary artery smooth muscle cells. Life Sci. 2011;89:644-649.
29. Bonnet S, Rochefort G, Sutendra G, et al. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci U S A. 2007;104:11418-11423.
30. Parpaite T, Cardouat G, Mauroux M, et al. Effect of hypoxia on TRPV1 and TRPV4 channels in rat pulmonary arterial smooth muscle cells [published online ahead of print March 24, 2015]. Pflugers Arch Eur J Phys-iol. 2015. doi: 10.1007/s00424-015-1704-6.
31. Paulin R, Courboulin A, Meloche J, et al. Signal transducers and activators of transcription-3/pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension. Circulation. 2011;123: 1205-1215.
32. Shen T, Wang N, Yu X, et al. The critical role of dynamin-related protein 1 in hypoxia-induced pulmonary vascular angiogenesis. J Cell Biochem. 2015;116:1993-2007.
33. Alva JA, Iruela-Arispe ML. Notch signaling in vascular morphogenesis. Curr Opin Hematol. 2004;11:278-283.
34. Villa N, Walker L, Lindsell CE, et al. Vascular expression of Notch pathway receptors and ligands is restricted to arterial vessels. Mech Dev. 2001;108:161-164.
35. Morimoto M, Liu Z, Cheng HT, et al. Canonical Notch signaling in the developing lung is required for determination of arterial smooth muscle cells and selection of Clara versus ciliated cell fate. J Cell Sci. 2010;123: 213-224.
36. Varadkar P, Kraman M, Despres D, et al. Notch2 is required for the proliferation of cardiac neural crest-derived smooth muscle cells. Dev Dyn. 2008;237:1144-1152.
37. Fouillade C, Monet-Lepretre M, Baron-Menguy C, et al. Notch signalling in smooth muscle cells during development and disease. Cardiovasc Res. 2012;95:138-146.
38. Li X, Zhang X, Leathers R, et al. Notch3 signaling promotes the development of pulmonary arterial hypertension. Nat Med. 2009;15:1289-1297.
39. Wang W, Liu J, Ma A, et al. mTORC1 is involved in hypoxia-induced pulmonary hypertension through the activation of Notch3. J Cell Physiol. 2014;229:2117-2125.
40. Xiao Y, Gong D, Wang W. Soluble JAGGED1 inhibits pulmonary hypertension by attenuating notch signaling. Arterioscler Thromb Vasc Biol. 2013;33:2733-2739.
41. Yamamura H, Yamamura A, Ko EA, et al. Activation of Notch signaling by short-term treatment with Jagged-1 enhances store-operated Ca(2+) entry in human pulmonary arterial smooth muscle cells. Am J Physiol Cell Physiol. 2014;306:C871-C878.
42. Krishna M, Narang H. The complexity of mitogen-activated protein kinases (MAPKs) made simple. Cell Mol Life Sci. 2008;65:3525-3544.
43. Munshi A, Ramesh R. Mitogen-activated protein kinases and their role in radiation response. Genes Cancer. 2013;4:401-408.
44. Yang S, Sharrocks AD, Whitmarsh AJ. MAP kinase signalling cascades and transcriptional regulation. Gene. 2013;513:1-13.
45. Biasin V, Chwalek K, Wilhelm J, et al. Endothelin-1 driven proliferation of pulmonary arterial smooth muscle cells is c-fos dependent. Int J Bio-chem Cell Biol. 2014;54:137-148.
46. Lu X, Bijli KM, Ramirez A, et al. Hypoxia downregulates PPARg via an ERK1/2-NF-kB-Nox4-dependent mechanism in human pulmonary artery smooth muscle cells. Free Radic Biol Med. 2013;63:151-160.
47. Yosimichi G, Nakanishi T, Nishida T, et al. CTGF/Hcs24 induces chon-drocyte differentiation through a p38 mitogen-activated protein kinase (p38MAPK), and proliferation through a p44/42 MAPK/extracellular-signal regulated kinase (ERK). Eur J Biochem. 2001;268:6058.
48. Zhao G, Seng J, Beagle J, et al. Heparin reduces overcirculation-induced pulmonary artery remodeling through P38 MAPK in piglet. Ann Thorac Surg. 2015;99:1677-1684.
49. Wilson JL, Yu J, Taylor L, et al. Hyperplastic growth of pulmonary artery smooth muscle cells from Subjects with pulmonary arterial hypertension is activated through JNK and p38 MAPK. PLoS One. 2015;10: e123662.
50. Jin C, Guo J, Qiu X, et al. IGF-1 induces iNOS expression. J Recept Signal Transduct Res. 2014;34:325-331.
51. Sartori R, Gregorevic P, Sandri M. TGFb and BMP signaling in skeletal muscle: potential significance for muscle-related disease. Trends Endo-crinol Metab. 2014;25:464-471.
52. Ma L, Chung WK. The genetic basis of pulmonary arterial hypertension. Hum Genet. 2014;133:471-479.
53. Fantozzi I, Platoshyn O, Wong AH, et al. Bone morphogenetic protein-2 upregulates expression and function of voltage-gated K+ channels in human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2006;291:L993-L1004.
54. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest. 2012;122:4306-4313.
55. Wu J, Yu Z, Su D. BMP4 protects rat pulmonary arterial smooth muscle cells from apoptosis by PI3K/AKT/Smad1/5/8 signaling. Int J Mol Sci. 2014;15:13738-13754.
56. Wang J, Fu X, Yang K, et al. Hypoxia inducible factor 1 dependent upregulation of BMP4 mediates hypoxia-induced increase of TRPC expression in PASMCs. Cardiovasc Res. 2015;107:108-118.
57. Ghahhari NM, Babashah S. Interplay between microRNAs and WNT/b-catenin signalling pathway regulates epithelial-mesenchymal transition in cancer. Eur J Cancer. 2015;51:1638-1649.
58. Pataki CA, Couchman JR, Brabek J. Wnt signaling cascades and the roles of syndecan proteoglycans. J Histochem Cytochem. 2015;63:465-480.
59. De A. Wnt/Ca2+ signaling pathway: a brief overview. Acta Biochim Biophys Sin (Shanghai). 2011;43:745-756.
60. Kahn M. Can we safely target the WNT pathway? Nat Rev Drug Discov. 2014;13:513-532.
61. de Jesus Perez V, Yuan K, Alastalo T, et al. Targeting the Wnt signaling pathways in pulmonary arterial hypertension. Drug Discov Today. 2014; 19:1270-1276.
62. Chiurillo MA. Role of the Wnt/b-catenin pathway in gastric cancer: an in-depth literature review. World J Exp Med. 2015;5:84-102.
63. Quasnichka H, Slater SC, Beeching CA, et al. Regulation of smooth muscle cell proliferation by b -catenin/T-cell factor signaling involves modulation of cyclin D1 and p21 expression. Circ Res. 2006;99:1329-1337.
64. Sklepkiewicz P, Schermuly RT, Tian X, et al. Glycogen synthase kinase 3beta contributes to proliferation of arterial smooth muscle cells in pulmonary hypertension. PLoS One. 2011;6:e18883.
65. Yu XM, Wang L, Li JF, et al. Wnt5a inhibits hypoxia-induced pulmonary arterial smooth muscle cell proliferation by downregulation of beta-catenin. Am J Physiol Lung Cell Mol Physiol. 2013;304:L103-L111.
66. de Jesus Perez VA, Alastalo TP, Wu JC, et al. Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt-beta-catenin and Wnt-RhoA-Rac1 pathways. J Cell Biol. 2009;184:83-99.
67. Sakao S, Tatsumi K. Vascular remodeling in pulmonary arterial hypertension: multiple cancer-like pathways and possible treatment modalities. Int J Cardiol. 2011;147:4-12.
68. Zhao L, Ashek A, Wang L, et al. Heterogeneity in lung 18FDG uptake in PAH: potential of dynamic 18FDG-PET with kinetic analysis as a bridging biomarker for pulmonary remodeling targeted treatments. Circulation. 2013;128:1214-1224.
69. Dromparis P, Paulin R, Stenson TH, et al. Attenuating endoplasmic reticulum stress as a novel therapeutic strategy in pulmonary hypertension. Circulation. 2013;127:115-125.
70. Bonnet S. An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation. 2006;113:2630-2641.
71. Rehman J, Archer SL. A proposed mitochondrial-metabolic mechanism for initiation and maintenance of pulmonary arterial hypertension in fawn-hooded rats: the Warburg model of pulmonary arterial hypertension. Adv Exp Med Biol. 2010;661:171-185.
72. Zeng Y, Liu H, Kang K, et al. Hypoxia inducible factor-1 mediates expression of miR-322: potential role in proliferation and migration of pulmonary arterial smooth muscle cells. Sci Rep. 2015;5:12098.
73. Danielsen PH, Moller P, Jensen KA, et al. Oxidative stress, DNA damage, and inflammation induced by ambient air and wood smoke partic-ulate matter in human A549 and THP-1 cell lines. Chem Res Toxicol. 2011;24:168-184.
74. Federici C, Drake KM, Rigelsky CM, et al. Increased mutagen sensitivity and DNA damage in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2015;192:219-228.
75. Vaillancourt M, Ruffenach G, Meloche J, et al. Adaptation and remodelling of the pulmonary circulation in pulmonary hypertension. Can J Cardiol. 2015;31:407-415.
76. Meloche J, Pflieger A, Vaillancourt M, et al. Role for DNA damage signaling in pulmonary arterial hypertension. Circulation. 2014;129: 786-797.
77. Meloche J, Le Guen M, Potus F, et al. MiR-223 reverses experimental pulmonary arterial hypertension. Am J Physiol Cell Physiol. 2015;309: C363-C372.
78. Li M, Vattulainen S, Aho J, et al. Loss of bone morphogenetic protein receptor 2 is associated with abnormal DNA repair in pulmonary arterial hypertension. Am J Respir Cell Mol Biol. 2014;50:1118-1128.
79. Ngo J, Matsuyama M, Kim C, et al. Bax deficiency extends the survival of Ku70 knockout mice that develop lung and heart diseases. Cell Death Dis. 2015;6:e1706.
80. Paplomata E, O'Regan R. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol. 2014;6:154-166.
81. Fan Z, Li C, Qin C, et al. Role of the PI3K/AKT pathway in modulating cytoskeleton rearrangements and phenotype switching in rat pulmonary arterial vascular smooth muscle cells. DNA Cell Biol. 2014;33:12-19.
82. Kong D, Yamori T. ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system. Acta Pharmacol Sin. 2010;31:1189-1197.
83. Mouchaers KTB, Schalij I, de Boer MA, et al. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil. Eur Respir J. 2010;36:800-807.
84. Dahal BK, Kosanovic D, Pamarthi PK, et al. Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension. Eur Respir J. 2010;36:808-818.
85. Watson G, Oliver E, Zhao L, et al. Pulmonary hypertension: old targets revisited (statins, PPARs, beta-blockers). Handb Exp Pharmacol. 2013; 218:531-548.
86. Wilkins MR, Ali O, Bradlow W, et al. Simvastatin as a treatment for pulmonary hypertension trial. Am J Respir Crit Care Med. 2010;181: 1106-1113.
87. Liu T, Li Y, Lin K, et al. Regulation of S100A4 expression via the JAK2-STAT3 pathway in rhomboid-phenotype pulmonary arterial smooth muscle cells exposure to hypoxia. Int J Biochem Cell Biol. 2012;44:1337-1345.
88. Nakamura K, Akagi S, Ogawa A, et al. Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. Int J Cardiol. 2012;159: 100-106.
89. Schermuly RT. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005;115:2811-2821.
90. Courboulin A, Barrier M, Perreault T, et al. Plumbagin reverses proliferation and resistance to apoptosis in experimental PAH. Eur Respir J. 2012;40:618-629.
91. Yang J, Li X, Al-Lamki RS, et al. Sildenafil potentiates bone morpho-genetic protein signaling in pulmonary arterial smooth muscle cells and in experimental pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2012;33:34-42.
92. Trottier-Boucher MN, Lapointe A, Malo J, et al. Sildenafil for the treatment of pulmonary arterial hypertension in infants with bronchopulmo-nary dysplasia. Pediatr Cardiol. 2015;36:1255-1260.
93. Tan K, Krishnamurthy MB, O'Heney JL, et al. Sildenafil therapy in bronchopulmonary dysplasia-associated pulmonary hypertension: a retrospective study of efficacy and safety. Eur J Pediatr. 2015;174: 1109-1115.
94. Dardi F, Manes A, Palazzini M, et al. Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights. Eur Respir J. 2015;46:414-421.
95. Kimura M, Tamura Y, Takei M, et al. Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study. BMC Pulm Med. 2015;15:62.
96. Galie N, Ghofrani AH. New horizons in pulmonary arterial hypertension therapies. Eur Respir Rev. 2013;22:503-514.
97. Hansmann G, de Jesus Perez VA, Alastalo T, et al. An antiproliferative BMP-2/PPARg/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest. 2008;118:1846-1857.
98. Koz1owska H, Baranowska-Kuczko M, Schlicker E, et al. Relaxation of human pulmonary arteries by PPARg agonists. Naunyn Schmiedebergs Arch Pharmacol. 2013;386:445-453.